$SNY News

SANOFI-ADR (NASDAQ:SNY): A Quality Dividend Stock with a 5.31% Yield and Strong Fundamentals

Sanofi Announces Data From ElevAATe Phase 2 Trial Shows Superiority Of Investigational Efdoralprin Alfa Over Standard-Of-Care Therapy For Treatment Of Alpha-1 Antitrypsin Deficiency-Related Emphysema

Sanofi (NASDAQ:SNY) Emerges as a Decent Value Pick with Strong Fundamentals

Vicore Pharma Elects Peter Guenter to its Board of Directors

Novavax, Inc. Q1 2026 Earnings Call Summary

Sanofi’s Dynavax Deal Reshapes Vaccine Portfolio And Valuation Narrative

Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1

'Sanofi Asks To Pull Diabetes Drug Out Of FDA Voucher Program After Political Appointee Interfered With Review' - STAT News

Sanofi invests $294M to expand AI Center of Excellence in Toronto and accelerate innovation for patients

European Equities Traded in the US as American Depositary Receipts Start Week Lower

Sanofi Expands Toronto AI Centre With $294M Investment; Invest Ontario Fund To Contribute A Conditional Grant Of Up To $5M

Sanofi (NASDAQ:SNY): A High-Yield Dividend Stock with Strong Fundamentals and a 5.26% Payout

The 28th China Beijing International High-Tech Expo Grand Opening Soon

Systemic Mastocytosis (SM) Treatment Market 2026-2035: Industry to More Than Double in Size, Led by Sanofi, AdvaCare Pharma, and Cogent Biosciences

Sanofi (ENXTPA:SAN) Valuation After Cenrifki Progress New CEO Appointment And Stronger Dupixent Momentum

Sanofi shares are trading higher after the company reported better-than-expected Q1 financial results.

Sanofi 2026 Q1 - Results - Earnings Call Presentation

Sanofi Maintains 2026 Guidance With High Single-Digit Sales Growth At CER, Business EPS Seen Growing Faster

Sanofi Q1 Adj. EPS $1.10 Beats $1.06 Estimate, Sales $12.307B Beat $11.990B Estimate

Sanofi Eyes First On-Body Injector Cancer Therapy As FDA Delays Decision